Portola leads with $46 million second round.
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Portola Pharmaceuticals
|
$46 million
|
Advanced Technology Ventures |
The money will be used to advance its lead candidate, an oral Factor Xa, into Phase II. |
|
PTC Therapeutics
|
$26.6 million
|
Credit Suisse First Boston Private Equity and HBM BioVentures |
The money will be used to develop PTC124 and advance its preclinical oncology and antiviral programs. |
|
Fovea Pharmaceuticals
|
$25 million
|
Sofinnova Partners |
The biotech is working on breakthrough treatments of retinal diseases. |
|
Mersana
|
$21 million
|
Fidelity Biosciences and ProQuest Investments |
Mersana is developing cancer therapeutics. |
|
OncoMethylome Sciences
|
$17.5 million
|
Edmond de Rothschild Investment Partners |
The company is developing molecular gene methylation tests for early cancer detection. |